Determination	O
of	O
As	O
metabolites	O

We	O
assessed	O
As	O
metabolism	O
using	O
the	O
percentages	O
of	O
iAs	O
,	O
MMA	O
,	O
and	O
DMA	O
in	O
urine	B-Organism_substance
,	O
as	O
well	O
as	O
two	O
methylation	O
indexes	O
[	O
i	O
.	O
e	O
.	O
,	O
primary	O
methylation	O
index	O
(	O
PMI	O
)	O
,	O
defined	O
as	O
the	O
ratio	O
between	O
MMA	O
and	O
iAs	O
,	O
and	O
secondary	O
methylation	O
index	O
(	O
SMI	O
)	O
,	O
defined	O
as	O
the	O
ratio	O
between	O
DMA	O
and	O
MMA	O
.	O

We	O
used	O
total	O
urinary	B-Organism_substance
As	O
[	O
U	O
-	O
As	O
;	O
the	O
sum	O
of	O
As	O
metabolites	O
(	O
iAs	O
+	O
MMA	O
+	O
DMA	O
)	O
in	O
urine	B-Organism_substance
]	O
as	O
the	O
measure	O
of	O
iAs	O
exposure	O
.	O

Concentrations	O
of	O
As	O
metabolites	O
in	O
urine	B-Organism_substance
were	O
measured	O
with	O
an	O
Agilent	O
1100	O
HPLC	O
system	O
(	O
Agilent	O
Technologies	O
,	O
Waldbronn	O
,	O
Germany	O
)	O
,	O
coupled	O
with	O
hydride	O
generation	O
(	O
HG	O
)	O
inductively	O
coupled	O
plasma	B-Organism_substance
mass	O
spectrometry	O
(	O
ICPMS	O
)	O
(	O
Agilent	O
7500ce	O
series	O
;	O
Agilent	O
Technologies	O
,	O
Japan	O
)	O
.	O

The	O
method	O
measures	O
metabolites	O
of	O
iAs	O
[	O
iAs	O
(	O
III	O
)	O
,	O
iAs	O
(	O
V	O
)	O
,	O
MMA	O
,	O
and	O
DMA	O
]	O
,	O
but	O
not	O
organic	O
As	O
species	O
(	O
e	O
.	O
g	O
.	O
,	O
arsenobetaine	O
,	O
arsenocholine	O
)	O
originating	O
from	O
the	O
diet	O
,	O
because	O
those	O
arsenicals	O
do	O
not	O
form	O
volatile	O
arsines	O
(	O
hydride	O
generation	O
)	O
like	O
iAs	O
and	O
its	O
metabolites	O
do	O
.	O

The	O
method	O
was	O
described	O
in	O
detail	O
by	O
Lindberg	O
et	O
al	O
.	O

(	O
2006	O
)	O
.	O

Determination	O
limits	O
were	O
0	O
.	O
1	O
mug	O
/	O
L	O
for	O
arsenite	O
[	O
As	O
(	O
III	O
)	O
]	O
and	O
MMA	O
and	O
0	O
.	O
2	O
mug	O
/	O
L	O
for	O
DMA	O
and	O
arsenate	O
[	O
As	O
(	O
V	O
)	O
]	O
.	O

We	O
adjusted	O
As	O
concentrations	O
for	O
variations	O
in	O
dilution	O
by	O
specific	O
gravity	O
(	O
to	O
the	O
mean	O
value	O
of	O
1	O
.	O
012	O
g	O
/	O
mL	O
)	O
;	O
U	O
-	O
Cre	O
,	O
which	O
is	O
commonly	O
used	O
for	O
dilution	O
adjustment	O
,	O
was	O
influenced	O
more	O
by	O
age	O
and	O
nutrition	O
than	O
was	O
specific	O
gravity	O
,	O
and	O
U	O
-	O
Cre	O
was	O
also	O
associated	O
with	O
urinary	B-Organism_substance
As	O
(	O
Nermell	O
et	O
al	O
.	O
2007	O
)	O
.	O

For	O
quality	O
control	O
purposes	O
,	O
we	O
analyzed	O
the	O
reference	O
material	O
(	O
CRM	O
No	O
.	O
18	O
;	O
National	O
Institute	O
for	O
Environmental	O
Studies	O
,	O
Ibaraki	O
,	O
Japan	O
)	O
with	O
a	O
certified	O
DMA	O
concentration	O
of	O
36	O
+	O
/	O
-	O
9	O
mug	O
/	O
L	O
together	O
with	O
the	O
collected	O
urine	B-Organism_substance
samples	I-Organism_substance
.	O

The	O
concentration	O
of	O
DMA	O
was	O
41	O
+	O
/	O
-	O
3	O
.	O
4	O
mug	O
/	O
L	O
(	O
mean	O
+	O
/	O
-	O
SD	O
;	O
n	O
=	O
18	O
)	O
.	O

Urine	B-Organism_substance
samples	I-Organism_substance
were	O
also	O
analyzed	O
for	O
As	O
metabolites	O
by	O
atomic	O
fluorescence	O
spectrometry	O
(	O
AFS	O
)	O
and	O
for	O
the	O
sum	O
of	O
As	O
metabolites	O
by	O
atomic	O
absorption	O
spectrometry	O
(	O
AAS	O
)	O
,	O
as	O
reported	O
by	O
Lindberg	O
et	O
al	O
.	O

(	O
2007a	O
)	O
.	O

The	O
results	O
of	O
ICPMS	O
and	O
AFS	O
showed	O
good	O
agreement	O
for	O
all	O
metabolites	O
;	O
for	O
iAs	O
[	O
As	O
(	O
III	O
)	O
+	O
As	O
(	O
V	O
)	O
]	O
,	O
MMA	O
,	O
and	O
DMA	O
,	O
R2	O
=	O
0	O
.	O
91	O
,	O
0	O
.	O
91	O
,	O
and	O
0	O
.	O
97	O
,	O
respectively	O
(	O
n	O
=	O
221	O
)	O
.	O

Further	O
,	O
we	O
obtained	O
good	O
agreement	O
for	O
the	O
sum	O
of	O
As	O
metabolites	O
between	O
the	O
three	O
different	O
methods	O
(	O
for	O
ICPMS	O
vs	O
.	O
AFS	O
,	O
R2	O
=	O
0	O
.	O
97	O
;	O
for	O
ICPMS	O
vs	O
.	O
AAS	O
,	O
R2	O
=	O
0	O
.	O
96	O
(	O
n	O
=	O
221	O
)	O
.	O

